Moderna's top scientist Paul Burton said the company has learned how to make better recruitments from diverse populations for its clinical trials from running its COVID-19 vaccine studies. "To get good uptake...you need to have representation of all sorts of people," Burton said, adding the company was eventually able to enrol 37% of its 35,000-person trial from communities of colour.